查阿尔茨海默病是否准备好进入黄金时段? 问问威尔逊和容纳
Miyo K Chatanaka1, Maria Pascual Lorén2,3, Eleftherios P Diamandis2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Critical reviews in clinical laboratory sciences
|August 5, 2025
概括
目前不建议对阿尔茨海默病 (AD) 进行查,因为对益处与危害的证据不足. 尽管取得了进展,但成本和缺乏有效治疗方法等挑战阻止了AD广泛查.
科学领域:
- 神经学 神经学
- 预防医学 预防医学
- 公共卫生 公共卫生
背景情况:
- 人口查对于预防疾病至关重要,但需要仔细评估好处与危害.
- 阿尔茨海默病 (AD) 的患病率正在上升,需要讨论查可行性.
- 最近的治疗和诊断进展促使重新评估AD查策略.
研究的目的:
- 评估人口查预症状或早期症状阿尔茨海默病的可行性.
- 将威尔逊和容纳的一般查原则应用于阿尔茨海默病.
- 审查关于认知障碍和AD查的当前指南和专家意见.
主要方法:
- 关于阿尔茨海默病查的已发表证据和专家意见的审查.
- 已建立的选标准的应用 (威尔逊和格纳的10条规则).
- 分析了USPSTF和CTFPHC等机构最近的指导方针.
主要成果:
- 目前的证据不足以推对认知障碍 (AD症状) 的查.
- 存在重大挑战,包括缺乏训练有素的专业人员,高成本和无效的治疗方法.
- 专家们对于AD的最佳测试和治疗策略仍然存在分歧.
结论:
- 尽管取得了进展,但目前对阿尔茨海默病的人口查并没有正当理由.
- 抗阿茲海默症查的潛在好處和危害需要進一步研究.
- 在实施AD查之前,解决诸如医疗保健能力和治疗疗效等系统性问题至关重要.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
29.8K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.0K
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Dementia
687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
687
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
